Invitrogen™ Tildrakizumab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541986	100 μg

Catalog No. PIMA541986 Supplier Invitrogen™ Supplier No. MA541986

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Tildrakizumab is a high-affinity, humanized, IgG1 kappa antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3. The Food and pharmaceutical Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7. A study was performed on the pharmacokinetics of this pharmaceutical on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5.

Specifications

• Antigen: Tildrakizumab Humanized
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 1.06 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: SCH900222; MK-3222
• Host Species: Human
• Immunogen: Human IL23A.
• Purification Method: Protein A
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov